Sato Keijiro, Sumi Masahiko, Ueki Toshimitsu, Kaiume Hiroko, Kirihara Takehiko, Takeda Wataru, Kurihara Taro, Hiroshima Yuki, Ueno Mayumi, Ichikawa Naoaki, Sato Takako, Ogata Masao, Fukuda Takahiro, Kobayashi Hikaru
Department of Hematology, Nagano Red Cross Hospital.
Rinsho Ketsueki. 2015 Apr;56(4):406-11. doi: 10.11406/rinketsu.56.406.
Human herpesvirus-6 (HHV-6) is known to cause critical encephalitis, as a central nervous system infection, in some hematopoietic stem cell transplantation (HSCT) recipients. Chromosomally integrated human herpesvirus-6 (CIHHV-6) persistently shows HHV-6 DNA in blood, but this does not necessarily suggest active infection. The true clinical significance in HSCT is not clear. The prevalence of CIHHV-6 in Japan is reportedly 0.21%. We herein report two HSCTs: from a CIHHV-6-positive donor to a negative recipient and from a negative donor to a positive recipient. In the CIHHV-6-positive donor case, the recipient's plasma, which had been negative for HHV-6 before HSCT, became positive after transplantation and the level then remained high, although the subject was asymptomatic. In the CIHHV-6-positive recipient case, the patient's plasma viral load was high just after transplantation, although the subject was asymptomatic, and the load gradually decreased after engraftment. Antivirals had no effect on the viral load in either case. We should consider CIHHV-6 when the HHV-6 DNA load in blood persists asymptomatically after HSCT, to avoid misdiagnosis of reactivated HHV-6 infection and overuse of antivirals. It is also useful to monitor HHV-6 DNA in blood before HSCT, to distinguish HHV-6 reactivation from CIHHV-6.
已知人类疱疹病毒6型(HHV-6)会在一些造血干细胞移植(HSCT)受者中引发严重脑炎,作为一种中枢神经系统感染。染色体整合型人类疱疹病毒6型(CIHHV-6)在血液中持续显示HHV-6 DNA,但这不一定意味着存在活动性感染。其在HSCT中的真正临床意义尚不清楚。据报道,CIHHV-6在日本的患病率为0.21%。我们在此报告两例HSCT病例:一例是从CIHHV-6阳性供体到阴性受体,另一例是从阴性供体到阳性受体。在CIHHV-6阳性供体的病例中,受者的血浆在HSCT前HHV-6呈阴性,移植后变为阳性,且此后水平一直很高,尽管该受试者没有症状。在CIHHV-6阳性受体的病例中,患者的血浆病毒载量在移植后即刻很高,尽管该受试者没有症状,且在植入后病毒载量逐渐下降。在这两种情况下,抗病毒药物对病毒载量均无影响。当HSCT后血液中的HHV-6 DNA载量无症状持续存在时,我们应考虑CIHHV-6,以避免对HHV-6再激活感染的误诊和抗病毒药物的过度使用。在HSCT前监测血液中的HHV-6 DNA也有助于区分HHV-6再激活和CIHHV-6。